Clinical trials: Resectable Pancreatic Adenocarcinoma
Ductal Adenocarcinoma of the Pancreas
Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
The aim ot the study is to investigate the efficacy and safety of two new intensified chemotherapy regimens (gemcitabine (Gem)/nab- paclitaxel (PAC), FOLFIRINOX) as neoadjuvant chemotherapy protocol in locally advanced…
- Trial name
- NEOLAP (NCT02125136)
- Testing
- Gem/nab-Pac, FOLFIFINOX
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- AIO-Studien-gGmbH
Cancer of Pancreas, Pancreas Adenocarcinoma
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
Relapses free survival will be evaluated as efficacy of carbon ions radiation therapy released before surgery.
- Conditions
- Cancer of Pancreas, Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
- Trial name
- PIOPPO (NCT03822936)
- Testing
- Preoperative chemotherapy, Preoperative radiotherapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Pancreatic Ductal Adenocarcinoma
Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma
More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low.
- Trial name
- NCT06344299
- Testing
- potential predictors
- Where
- China
- Volunteers
- 5,302 people
- Sponsor
- Fudan University
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
This phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC) that can be removed by surgery (resectable) or that may be between…
- Trial name
- NCT07748611
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Northwestern University
Pancreas Cancer
Intraoperative Radiation Therapy for Resectable Pancreas Cancer
Currently, for patients with pancreatic cancer the standard treatment is surgery followed by chemotherapy and/or radiation therapy.
- Trial name
- IORT (NCT02599662)
- Testing
- 10 Gy Low-KV IORT, 15 Gy Low-KV IORT, 20 GY Low-KV IORT
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Loyola University
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
- Trial name
- SHAPER (NCT04106856)
- Testing
- Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Pancreatic Adenocarcinoma Resectable, Non Metastatic
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
This is an open master platform trial, which includes multi neo-adjuvant treatment trials, multi-center, national. This platform trial evaluates the major pathological response rate (mPR) after surgery.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
- Trial name
- POWER (NCT07808567)
- Testing
- GnP, FOLFIRINOX
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer.
- Trial name
- NCT01962909
- Testing
- PTP-01
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Virginia
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
This is a clinical research study of an investigational (FDA BB-IND 10091) treatment for patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer responds to standard therapies.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- Macrobead (NCT01053013)
- Testing
- RENCA macrobeads
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- The Rogosin Institute
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-3 (NCT04927780)
- Testing
- Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride
- Where
- 21 sites in Netherlands, Sweden
- Volunteers
- 378 people
- Sponsor
- Erasmus Medical Center
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight.
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma
- Trial name
- NCT05642962
- Testing
- Pertzye
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Pancreatic Ductal Adenocarcinoma
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor…
- Trial name
- NEOiPANC (NCT03979066)
- Testing
- Atezolizumab, PEGPH20
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gulam Manji
Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma
FAZA PET/MRI Pancreas
This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer
- Trial name
- NCT04395469
- Testing
- 18F-FAZA
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499265
- Testing
- gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671
- Where
- 39 sites in Germany, Hungary and 4 more
- Volunteers
- 95 people
- Sponsor
- Heidelberg Pharma AG
Pancreatic Adenocarcinoma
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with…
- Trial name
- NCT04926467
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor Research Institute
Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic…
- Trial name
- NCT04969731
- Testing
- Immuncell-LC, Gemcitabine
- Where
- South Korea
- Volunteers
- 408 people
- Sponsor
- GC Cell Corporation
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center